Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Inventory (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Inventory for 7 consecutive years, with $17.4 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory rose 105.01% to $17.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.1 million through Dec 2025, down 18.58% year-over-year, with the annual reading at $23.1 million for FY2025, 18.58% down from the prior year.
  • Change in Inventory for Q4 2025 was $17.4 million at Akebia Therapeutics, up from -$6.9 million in the prior quarter.
  • The five-year high for Change in Inventory was $19.2 million in Q1 2021, with the low at -$24.5 million in Q4 2022.
  • Average Change in Inventory over 5 years is $3.0 million, with a median of $3.0 million recorded in 2023.
  • Peak annual rise in Change in Inventory hit 765.2% in 2021, while the deepest fall reached 4201.19% in 2021.
  • Over 5 years, Change in Inventory stood at -$10.3 million in 2021, then tumbled by 136.59% to -$24.5 million in 2022, then surged by 148.18% to $11.8 million in 2023, then dropped by 27.88% to $8.5 million in 2024, then soared by 105.01% to $17.4 million in 2025.
  • According to Business Quant data, Change in Inventory over the past three periods came in at $17.4 million, -$6.9 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.